anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Monitoring of blood levels has increased the efficacy and safety of anticonvulsants (see PRECAUTIONS, Laboratory Tests). Dosage should be adjusted to the needs of the individual patient. A low initial daily dosage with a gradual increase is advised. As soon as adequate control is achieved, the dosage may be reduced very gradually to the minimum effective level. Medication should be taken with meals.

Epilepsy (see  INDICATIONS AND USAGE)

Adults and children over 12 years of age-Initial: 200 mg twice a day for tablets (400 mg/day). Increase at weekly intervals by adding up to 200 mg/day using a three times a day or four times a day regimen of carbamazepine tablets until the optimal response is obtained. Dosage generally should not exceed 1,000 mg daily in children 12 to 15 years of age, and 1200 mg daily in patients above 15 years of age. Doses up to 1600 mg daily have been used in adults in rare instances. Maintenance: Adjust dosage to the minimum effective level, usually 800 to 1200 mg daily.

Children 6 to 12 years of age-Initial: 100 mg twice a day for tablets (200 mg/day). Increase at weekly intervals by adding up to 100 mg/day using a three times a day or four times a day regimen of carbamazepine tablets until the optimal response is obtained. Dosage generally should not exceed 1,000 mg daily. Maintenance: Adjust dosage to the minimum effective level, usually 400 to 800 mg daily.

Children under 6 years of age-Initial: 10 to 20 mg/kg/day twice a day or three times a day as tablets. Increase weekly to achieve optimal clinical response administered three times a day or four times a day Maintenance: Ordinarily, optimal clinical response is achieved at daily doses below 35 mg/kg. If satisfactory clinical response has not been achieved, plasma levels should be measured to determine whether or not they are in the therapeutic range. No recommendation regarding the safety of carbamazepine for use at doses above 35 mg/kg/24 hours can be made.

Combination Therapy: Carbamazepine may be used alone or with other anticonvulsants. When added to existing anticonvulsant therapy, the drug should be added gradually while the other anticonvulsants are maintained or gradually decreased, except phenytoin, which may have to be increased (see PRECAUTIONS, Drug Interactions, and Pregnancy).

Trigeminal Neuralgia (see INDICATIONS AND USAGE)

Initial: On the first day, 100 mg twice a day for tablets for a total daily dose of 200 mg. This daily dose may be increased by up to 200 mg/day using increments of 100 mg every 12 hours for tablets, only as needed to achieve freedom from pain. Do not exceed 1200 mg daily. 

Maintenance: Control of pain can be maintained in most patients with 400 to 800 mg daily. However, some patients may be maintained on as little as 200 mg daily, while others may require as much as 1200 mg daily. At least once every 3 months throughout the treatment period, attempts should be made to reduce the dose to the minimum effective level or even to discontinue the drug.
The American Society of Shoulder and Elbow Therapists' consensus statement on rehabilitation following arthroscopic rotator cuff repair will be used as guideline for rehabilitation of patients (Thigpen, C. A., Shaffer, M. A., Gaunt, B. W., Leggin, B. G., Williams, G. R., \& Wilcox III, R. B. (2016). The American Society of Shoulder and Elbow Therapists' consensus statement on rehabilitation following arthroscopic rotator cuff repair. Journal of shoulder and elbow surgery, 25(4), 521-535.).
The present invention relates to methods and apparatus for measuring the condition of skin surface, particularly a potential condition. An object of the present invention is to provide a method and apparatus for simply measuring a potential condition of the skin surface, particularly without imparting pain to a human. In addition, another object of the present invention is to provide a method for digitalizing human senses derived from stimulation to the skin surface and a method for measuring the effect of a drug for warding off the stimulation. Means adopted for solving the problems are to measure the potential difference between a skin section, which is floated on the surface of a culture solution, and the culture solution, and to impart stimulation to the skin or to add a drug further upon measurement in order to carry out the measurement. Furthermore, upon measuring the skin surface potential condition, a sublingual potential is used as a standard. From the foregoing, the potential condition of the skin surface can be measured simply, particularly without imparting pain to a human, enabling for digitalization of the condition of stimulation to the skin surface and assessment and development of a drug for warding off stimulation.
Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in Western countries. CLL is a highly heterogeneous disease: some patients may never require therapy and others relapse several times after different therapeutic strategies. Therefore, in CLL, prognostic markers are essential to capture high-risk patients for different clinical endpoints including early treatment requirement, early progression after BTK or BCL2 inhibitors and Richter transformation. In early stage CLL, different biological and clinical biomarkers have been identified to predict time to treatment requirement that could be used to identify the most appropriate population for early intervention clinical trial. However, at the moment, the standard of care for early stage CLL remains watch & wait since no survival benefit has been identified in clinical trials with chemoimmunotherapy and with BTK inhibitors. In patients requiring treatment TP53 disruptions identify high-risk patients who benefit the most from long-term continuous therapy with BTKi. On the opposite side of the spectrum, IGHV mutated patients devoid of TP53 disruption benefit the most from fixed-duration therapy with venetoclax-obinutuzumab. In between, the highly heterogenous subgroup of patients with IGHV unmutated genes represents the group in which further efforts are needed to identify additional prognostic biomarkers aimed at selecting patients who can benefit from fixed-duration and patients who can benefit from long term BTKi therapy. In the context of the aggressive transformation of CLL, namely Richter syndrome, the clonal relationship to the CLL counterpart represents the strongest prognostic biomarker. Clonally related Richter syndrome still represents an unmet clinical need which requires further efforts to identify new therapeutic strategies.
With current approaches to HIV care, patients generally do not qualify for expedited services until they have been in care for 6 to 12 months. Once they have achieved an undetectable viral load and/or high adherence, patients qualify for expedited services with fewer clinic visits. The problem with this approach is that it's time-intensive early in ART care, when attrition rates are highest. A potential solution to this problem is to provide earlier fast-track care for patients on dolutegravir-based regimens with viral suppression. This strategy is feasible due to the high potency and rapid declines in viral load with dolutegravir-based regimens.

We will compare a strategy of early fast-track care (8 to 12 weeks, for patients with viral suppression) versus standard initiation of fast-track care (after 6 months in care, with viral suppression). All participants will receive the same ART regimen, the combination regimen of Tenofovir Disoproxil Fumarate-Lamivudine-Dolutegravir.
The jump rope exercise program was performed for 50 minutes with 5 minutes of warm-up and cool-down per day, 5 times a week for 12 weeks. The program consisted of various main jump rope exercises (1 line 2 jump, jumping feet together, running jumping, open side jump, open back and forth jump, rock paper scissor jump). The warm-up and cool down consisted of static stretching, walking, and jogging. Intensity of exercise was gradually increased from 40-50% heart rate reserve (HRR) in weeks 1-4 and to 60-70% HRR in weeks 9-12. Each training session was supervised by the researchers. Every subject wore a heart rate monitor during the whole training session in order to maintain the designated training intensity.
Placebo (20 mg/day) in a 10-5-5 schedule: 10 mg at 0700h, 5 mg at 1200h, and 5 mg at 1700h. The placebo periods last 10 weeks per period. In total, there are two placebo periods.
PROBLEM TO BE SOLVED: To obtain a suppression potentiator against irritancy due to irritants, containing a water-soluble-and-nitrogen-contg. biopolymer, and to obtain a cosmetic for protection from irritancy containing this suppression potentiator. SOLUTION: This suppression potentiator against irritancy contains 0.01-10wt.% of a water-soluble and nitrogen-contg. biopolymer such as mucin or collagen. The objective cosmetic for protecting the skin from irritants contains this biopolymer and 0.001-10wt.% of a compound of the formula (R1 is H or a 1-4C alkyl; R2 is a primary, secondary or tertiary 1-4C alkylamine or a quaternary 1-4C alkylammonium ion; (m) and (n) are each 1-4), its polymer or copolymer (pref. methacryloyloxyethylphosphorylcholine) as the essential ingredients. The cosmetics include skin cosmetics for protecting the skin from irritants, makeup cosmetics, cleansing agents, bathing agents, hair cosmetics for protecting the hair from irritants and manicures for protecting the nails from nitro compounds causing nail yellowing.
A healthy 32-year-old woman presented with binocular diplopia immediately after sustaining a penetrating injury to the left periocular adnexa with a hot metal skewer. Examination revealed an incomitant esotropia, with complete limitation of abduction of the left eye with downshoot in left gaze and normal afferent visual function. Computed tomography and magnetic resonance imaging demonstrated no fracture, but there was mild thickening of the medial rectus muscle and associated fat stranding. Lack of orbitomuscular tethering or hematoma led to the presumptive diagnosis of thermal cauterization injury causing left medial rectus restriction. Given the lack of literature on this mechanism of injury, the patient was monitored closely. She exhibited remarkable spontaneous improvement in motility over 6 months, with near orthophoria in primary gaze. However, bothersome residual esotropic diplopia in left gaze prompted a left medial rectus recession, with a good outcome. This case demonstrates that isolated extraocular muscle thermal injuries and consequential strabismus can recover spontaneously; longitudinal observation before surgical intervention may be appropriate in such cases.
The present invention provides a method for purifying N-substituted maleimide, specifically, N-phenyl maleimide. The method of the present invention purifies N-substituted maleimide produced by a reaction of a maleic acid anhydride and a primary amine from a reaction solution state dissolved in a non-polar solvent. The N-substituted maleimide solution is purified by using a silica gel column. Then, additional purification is performed through recrystallization, and impurities having low boiling points and residual solvents are removed through distillation. According to the present invention, a reaction solution state including N-substituted maleimide produced by a production process of N-substituted maleimide is intactly applied to a silica gel column, and thus a polymerization oligomer of N-substituted maleimide or red impurities which are an analogue of the polymerization oligomer are removed. Accordingly, the method is simple, and thus can contribute to improvement of production rates of N-substituted maleimide and can be industrially applied.
Patients receive cyclophosphamide IV, carboplatin IV, and thiotepa IV over 24 hours on days -7 to -4. PBSC are reinfused and G-CSF is administered as in arm I.
Decitabine starting dose of 10mg/m\^2 given daily via intravenous infusion on days 1-5 of 28 day cycle. Peginterferon Alfa-2b starting dose of 3 µg/kg injection under the skin once a week on days 1, 8, 15, and 21 of 28 day cycle.
Provided is a raw material for cosmetics; it can conveniently prepare cosmetics having stability, excellent feeling of use, and without skin irritation. The raw material for cosmetics according to the present invention includes a core-corona type microgel dispersion obtained by the radical polymerization of a polyethylene oxide macromonomers represented by the following formula (1), a hydrophobic monomer represented by the following formula (2), and a crosslinking monomer represented by the following formula (3) under the following conditions (A) ~ (E), (A) the charged molar quantity of the polyethylene oxide macromonomer / the charged molar quantity of the hydrophobic monomer, expressed by the molar ratio is 1: 10 to 1: 250. (B) the charged amount of the crosslinking monomer relating to the charged amount of the hydrophobic monomer, is 0.1 to 1.5% by mass. (C) the hydrophobic monomer represented by the following formula (2) has a monomer composition obtained by mixing one or more methacrylic acid derivatives having an alkyl group of 1 to 8 carbon atoms. (D) the polymerization solvent is water-polyol mixed solvent, the polyol is one or more selected from dipropylene glycol, 1,3-butylene glycol and isoprene glycol. (E) the solvent composition of the water-polyol mixed solvent has a mass ratio at 20 DEG C, water: polyol = 90 ~ 10:10~90. R1 represents an alkyl group having 1 to 3 carbon atoms, n is a number from 8 to 200. X represents H or CH3. R2 represents an alkyl group having 1 to 3 carbon atoms, R3 represents an alkyl group having 1 to 12 carbon atoms. R4 and R5 each independently represent an alkyl group having 1 to 3 carbon atoms, m is a number of 0 to 2.
Patients undergo radiosurgery on day 0. Within 2 weeks, patients undergo surgical resection.
The 2023 American Academy of Pediatrics' "Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents with Obesity (Obesity CPG)" is a comprehensive document that addresses the evaluation and treatment of pediatric obesity. Much attention has been focused on the use of medications and surgery to treat severe obesity, but the document also thoroughly reviews the evaluation of obesity and its comorbidities through key action statements and consensus recommendations. The majority of these evaluation guidelines are well within the scope of the general pediatrician and an understanding of and implementation of them can lead to improved obesity care in the primary care setting. The goal of this article is to guide the reader in the evaluation of obesity and its comorbidities in the primary care setting through a chronic disease model lens as a basis for all future care. [Pediatr Ann. 2024;53(10):e378-e385.].
Disability studies have been successfully focusing on individuals' lived experiences, the personalization of goals, and the constitution of the individual in defining disease and restructuring public understandings of disability. Although they had a strong influence in the policy making and medical modeling of disease, their framework has not been translated to traditional naturalistic accounts of disease. I will argue that, using new developments in evolutionary biology (Extended Evolutionary Synthesis [EES] about questions of proper function) and behavioral ecology (Niche conformance and construction about the questions of reference classes in biostatistics accounts), the main elements of the framework of disability studies can be used to represent life histories at the conceptual level of the two main "non-normative" accounts of disease. I chose these accounts since they are related to medicine in a more descriptive way. The success of the practical aspects of disability studies this way will be communicated without causing injustice to the individual since they will represent the individuality of the patient in two main naturalistic accounts of disease: the biostatistical account and the evolutionary functional account. Although most accounts criticizing the concept of disease as value-laden do not supply a positive element, disability studies can supply a good point for descriptive extension of the concept through inclusion of epistemic agency.
<P>PROBLEM TO BE SOLVED: To provide a therapeutic treatment method for maintaining neural pathways in a mammal cell; and to provide a composition and a device.  <P>SOLUTION: The therapeutic treatment method for maintaining the neural pathways includes enhancing survival of neurons at risk of dying, inducing cellular repair of neurons and the neural pathways, and maintaining their differentiated phenotype. In one embodiment, the invention provides means for stimulating CAM expression in the neurons. The invention also provides means for evaluating the status of nerve tissue, including means for detecting and monitoring neuropathies in a mammal. The method, device and composition include a morphogen-stimulating agent provided to the mammal in a therapeutically effective concentration.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Standard Dihydroartemisinin piperaquine (DHA PP) dosing according to national guidelines, oral administration of one dose per day for three consecutive days. Target dosing is 2-4 mg/kg for DHA and 20 mg/kg for PP. Children (\<30kg) will receive tablets of 20mg DHA and 160mg PP, while adults will receive tablets of 40mg DHA and 320mg PP.
Kinesio taping was applied on the skin over the rectus femoris muscle on one limb and 3M Micropore® (placebo tape) was applied on the contralateral limb. Different tapes were used to evaluate if tape type would affect the findings. The side of application of the different tapes was randomized among the participants. Half of the participants (n = 17) had KT applied to the left thigh and the other half to the right thigh (n = 17). KT was applied using the "V" technique, the knee was positioned at 45º of flexion, the origin of both tapes was located 10 cm below the anterior-superior iliac spine with one tape going laterally and one medially to the rectus femoris muscle belly, passing around the patella and finishing on the tibial tuberosity. The same technique was used for the Micropore tape on the contralateral limb, but because it is not elastic, the knee joint was not crossed and the end points were the medial and lateral aspects of the patella. The mean force values were calculated for each condition (pre, post and 24 hours after tape application). The isometric knee extension force was collected using a load cell (EMG System do Brasil Ltda. ®) with a measuring range from 0 to 200 kg at 1000 Hz, filtered with a low pass filter type Butterworth 4th order and cut-off frequency of 15 Hz, obtained through residual analysis.
A method of producing a custom fragrance is provided comprising the steps of selecting a series of basic scents. The scents are incorporated into a semi-solid or solid vehicle to produce a scented product. With the semi-solid vehicle the product will be in the form of a viscous cream, gel or ointment contained in a squeeze tube, jar or the like. The solid form will be wax-like and may be molded into a predetermined shape or cast into a wide-mouthed container or mechanical dispensing device. To carry-out the invention, a user transfers a selected product to a portion of one's skin or other surface. One or more additional scented products are selected and applied in the same manner. The products are then manually mixed together on the skin or other surface to form a custom fragrance in-situ.
The objective of this study is to assess the benefit of new super-power bone-anchored hearing aid (BAHA) processors in BAHA users. BAHAs are able to help people with mixed/conductive and single-sided hearing loss when they were not receiving benefit from traditional hearing aids or could not use them due to differences in their ears related to surgery or congenital anomalies. Stronger super-power processors may be able to help individuals who previously did not meet candidacy for BAHA. This study will evaluate how much benefit they are getting from their current devices compared to new super-power devices.

The information collected in this study may lead to improved evaluation of patients considering BAHA implantation and expanded treatment options for new and existing BAHA users. Primary outcome measures will include hearing threshold and speech perception measures. All devices are commercially available and FDA approved.
FIELD: medicine. SUBSTANCE: method involves applying chemoradiotherapy. Belustin is administered 20-28 h before carrying out the first fraction of radiotherapy treatment as chemotherapeutic preparation. Its taking is to be continued during the first 4-6 days of irradiation at a dose of 40 mg daily until total dose reaches 200-280 mg. Radiation therapy is to be carried out in dose multifractioning mode during 16 days. 10-14 days later, repeated chemoradiotherapy treatment is carried out during 14 days. Total radiation dose for two treatment courses makes up 70-72.5 Gr. Belustin is administered at a dose of 200 mg for 1-3 days during the following 3-6 months with 25-30 days long pauses. To increase treatment effectiveness, alpha-2- interferon is additionally administered. EFFECT: low risk of treatment-induced complications; prolonged patient life period without recidivation occurred. 2 cl
Surrogates will receive augmented usual care. The augmentation is that there will be 2 family meetings scheduled during the first 10 days of enrollment.
PROBLEM TO BE SOLVED: To obtain the subject composition containing fine pigment, fat phase and solid elastomeric polyorganosiloxane so as to increase the screening power of the fine pigment and afford excellent protective factor against rays of light. SOLUTION: This protective composition is obtained by incorporating a composition containing fine pigment consisting of at least one kind of metal oxide with a solid elastomeric polyorganosiloxane in combination with fat phase. In this case, the polyorganosiloxane, which is either partly or fully crosslinked, is pref. in gel form incorporated with a hydrocarbon oil and/or silicone oil, and accounts for 3-80wt.% of the mixture of the elastomeric polyorganosiloxane and fat phase and 0.3-60wt.% of the whole composition. The fine pigment, which is titanium dioxide or iron oxide each 10-60nm in particle size, accounts for 0.5-30wt.% of the whole composition. This composition is usable for makeup of or caring for the skin, antagonizes wrinkles/fine wrinkles, and is useful for protecting both the hair and skin.